Metabolism of the neuroprotectant ergothioneine as a blood-based biomarker of cognitive resilience to amyloid pathology

Joyce R. Chong, Irwin K. Cheah, Richard M. Y. Tang, Barry Halliwell, Christopher Chen, Mitchell K.p. LaimedRxiv 2025 · DOI

Abstract

Background: The mechanisms underlying cognitive resilience to Alzheimer’s disease (AD) pathology are under active investigation. The association between dietary micronutrients with neuroprotective properties and cognitive resilience is currently unknown. Objective: To investigate whether plasma L-ergothioneine (ET), its metabolite L-hercynine (HC), and their ratio (HC:ET, as an index of ET metabolism) affect the association between plasma markers of brain amyloid pathology (phosphorylated tau species) and cognitive decline. Design: Longitudinal cohort study of 259 dementia-free participants in Singapore (mean age 72) followed for up to 5 years. Results: Plasma HC:ET significantly moderated the association between plasma p-tau181 and cognitive decline. High HC:ET attenuated the detrimental effects of p-tau181 (High HC:ET β = 0.0976 vs. Low HC:ET β = 0.849). Participants with high amyloid risk and Low HC:ET had a twofold increased risk of cognitive decline (HR = 1.96) compared to those with High HC:ET. Conclusions: HC:ET is a potential biomarker of cognitive resilience, suggesting that ET metabolism may offer neuroprotection against AD-associated decline.

Introduction

In the study of Alzheimer’s Disease (AD), researchers have long observed a "cognitive reserve" paradox: some individuals maintain high cognitive function despite significant amyloid and tau pathology in the brain. While lifestyle factors like education and social engagement are known contributors to this resilience, the underlying molecular mechanisms remain elusive.

Oxidative stress is a primary driver of AD progression. This study focuses on L-ergothioneine (ET), a diet-derived antioxidant found in mushrooms and certain bacteria. Humans do not synthesize ET and must acquire it through diet. Once in the body, ET is converted to L-hercynine (HC) when it neutralizes reactive oxygen species (ROS). This study investigates whether the efficiency of this metabolic process, represented by the HC:ET ratio, serves as a chemical shield against the cognitive impact of amyloid pathology.

Methods

This longitudinal study followed 259 dementia-free participants from the Singapore memory clinic and community for a mean follow-up period of 52 months.

Biomarker and Cognitive Assessment

  • Metabolic Profiling: Plasma levels of ET and HC were measured using liquid chromatography-tandem mass spectrometry (LC–MS/MS). The HC:ET ratio was calculated to serve as an index of ET metabolic turnover.
  • Pathology Markers: Plasma phosphorylated tau (p-tau181 and p-tau217) were utilized as blood-based proxies for brain amyloid and tau burden.
  • Cognitive Outcomes: Cognitive health was tracked annually using the Clinical Dementia Rating Sum of Boxes (CDR-SB). Incident cognitive decline was defined as an increase in Global CDR scores (CDR-GS) of ≥ 0.5.

Results

The Moderation Effect of ET Metabolism

The study found that raw levels of ET or HC alone did not significantly moderate the relationship between pathology and decline. However, the HC:ET ratio emerged as a critical moderator.

For participants with a Low HC:ET ratio, higher levels of p-tau181 were strongly associated with faster cognitive decline (β = 0.849; 95% CI, 0.318 to 1.38). In contrast, for those with a High HC:ET ratio, this association was effectively decoupled (β = 0.0976; 95% CI = -0.444 to 0.639). This suggests that high metabolic turnover of ET protects neurons from the toxic effects of tau pathology.

Risk of Incident Decline

Among participants identified as high-risk for amyloid pathology based on p-tau levels, those with a low HC:ET ratio faced a twofold increased risk of incident cognitive decline (Hazard Ratio [HR] = 1.96; 95% CI = 1.01 to 3.79) compared to those with high metabolic efficiency (HR = 0.87; 95% CI = 0.33 to 2.26).

Stability vs. Decline

When comparing participants who remained cognitively stable against those who declined (despite both groups having high brain pathology), the stable group exhibited significantly higher HC:ET ratios (p = 0.046), reinforcing the role of ET metabolism in cognitive resilience.

Discussion

The findings suggest that the efficiency of the antioxidant response—how actively ET is being utilized to combat oxidative stress—is a more significant predictor of resilience than the absolute concentration of the antioxidant itself. A high HC:ET ratio likely indicates a robust, active defense system that mitigates the oxidative damage typically associated with amyloid buildup.

Limitations

While p-tau is a validated biomarker, the study lacked universal amyloid PET imaging or cerebrospinal fluid data, which are the gold standards for AD diagnosis. Additionally, as the study was conducted in a Singaporean cohort, the results may be influenced by regional dietary habits (e.g., high mushroom consumption) and genetic factors like the OCTN1 transporter gene.

Conclusion

Identifying the HC:ET ratio as a biomarker for cognitive resilience provides a new target for Alzheimer's intervention. Future research should focus on whether ET supplementation or strategies to enhance ET metabolism can therapeutically boost cognitive reserve and delay the onset of AD symptoms in high-risk populations.

Summary updated

Abstract

Abstract Background The mechanisms underlying cognitive resilience to Alzheimer’s disease (AD) pathology are under active investigation. The association between dietary micronutrients with neuroprotective properties and cognitive resilience is currently unknown. Objective To investigate whether plasma L-ergothioneine (ET), its metabolite L-hercynine (HC), as well as their ratio (HC:ET, as an index of ET metabolism) affect the association between plasma markers of brain amyloid pathology (phosphorylated tau species) and cognitive decline. Design, setting and participants This study consisted of 259 dementia-free participants (mean age [SD] = 72 [8] years; 50% females) recruited from memory clinics and the community in Singapore from August 2010 to July 2019 as part of a larger, ongoing longitudinal cohort study on dementia, with analyses performed in February 2025. Measurements All participants of this study were dementia-free at baseline (median Clinical Dementia Rating-Sum of Boxes (CDR-SB) [IQR] scores = 0 [1]), had blood collected for measurements of plasma ET, HC, HC:ET, p-tau181 and p-tau217, and underwent annual neuropsychological assessments for up to 5 years (mean follow-up [SD] = 52 [15] months). The main cognitive outcomes were cognitive decline, defined by annual change of CDR-SB, and risk of incident cognitive decline, defined as Global CDR scores (CDR-GS) increments of ≥ 0.5 at follow-up. Linear regression analyses tested for interaction effects of plasma ET, HC and HC:ET on the association between plasma p-tau and cognitive decline, while Cox proportional hazards models were fitted to estimate hazard ratios (HRs) of incident cognitive decline. Results Plasma HC:ET significantly moderated associations between plasma p-tau181 and cognitive decline, whereby only High HC:ET attenuated the detrimental effects of plasma p-tau181 on cognitive decline (High HC:ET β = 0.0976; 95% Confidence Interval [CI] = -0.444 to 0.639 vs. Low HC:ET β = 0.849; 95% CI, 0.318 to 1.38). Among participants with high risk of amyloid pathology, those with Low HC:ET had approximately twofold increased risk of cognitive decline (Hazards ratio [HR] = 1.96; 95% CI = 1.01 to 3.79) compared to participants with High HC:ET (HR=0.87; 95% CI = 0.33 to 2.26) over the follow-up period. Conclusions Identification of plasma HC:ET as a biomarker of cognitive resilience to amyloid pathology suggests potential beneficial effects of ET metabolism. Further studies are needed to elucidate ET-mediated neuroprotective mechanisms as potential therapeutic targets in delaying or moderating AD-associated cognitive decline.
BibTeX
@misc{chong2025metabolism,
  author = {Joyce R. Chong and Irwin K. Cheah and Richard M. Y. Tang and Barry Halliwell and Christopher Chen and Mitchell K.P. Lai},
  title = {{Metabolism of the neuroprotectant ergothioneine as a blood-based biomarker of cognitive resilience to amyloid pathology}},
  year = {2025},
  doi = {10.1101/2025.07.31.25332054},
  howpublished = {medRxiv},
}
Figure